跳至主要内容
临床试验/NCT02682849
NCT02682849已完成不适用

Prevention of Retained-Blood Outcomes With Active Clearance Technology- The ACT Registry

John M. Stulak1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2016年5月10日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
500
试验地点
1
主要终点
Number of interventions to Treat Retained Blood Syndrome

研究概览

简要总结

The purpose of this study is to evaluate the effectiveness of the PleuraFlow® Active Clearance Technology™ (ACT) System in the management of blood evacuation after cardiac surgery.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or Female subjects 18 years of age or older who received a PleuraFlow System following heart surgery.
  • Patient undergoing cardiac surgery via sternotomy

排除标准

  • Robotic surgery
  • Any access via thoracotomy
  • Any condition deemed inappropriate for inclusion by the investigators.
  • Intolerance to implantable silicone materials.

结局指标

主要结局

Number of interventions to Treat Retained Blood Syndrome

时间窗: Discharge from operating room for index-surgery through hospital discharge - approximate 30 days

Retained Blood Syndrome (RBS) is defined by a composite endpoint of specific reoperation for bleeding, pericardial effusion, and hemothorax.

次要结局

  • Number of episodes of new on set of post operative atrial fibrillations (POAS)(30 day)
  • Number of readmissions for any diagnosis of RBS or POAS re-occurrences(30 day)

研究者

发起方
John M. Stulak
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

John M. Stulak

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验